Profile data is unavailable for this security.
About the company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
- Revenue in USD (TTM)34.84m
- Net income in USD-74.62m
- Incorporated2001
- Employees123.00
- LocationMersana Therapeutics Inc840 Memorial DrCAMBRIDGE 02139-3789United StatesUSA
- Phone+1 (617) 498-0020
- Fax+1 (302) 655-5049
- Websitehttps://www.mersana.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Inc | 40.56m | -179.28m | 226.12m | 168.00 | -- | 0.6385 | -- | 5.58 | -2.53 | -2.53 | 0.5709 | 4.98 | 0.0783 | -- | 15.49 | 241,428.60 | -34.61 | -47.40 | -38.88 | -54.18 | -- | -- | -442.15 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Biomea Fusion Inc | 0.00 | -144.01m | 231.20m | 107.00 | -- | 3.04 | -- | -- | -4.00 | -4.00 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -85.85 | -- | -98.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Neurogene Inc | 925.00k | -71.13m | 231.59m | 91.00 | -- | 1.48 | -- | 250.36 | -4.49 | -4.49 | 0.0582 | 10.56 | 0.0073 | -- | -- | 10,164.83 | -56.07 | -32.70 | -61.14 | -34.73 | -- | -- | -7,689.95 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Fate Therapeutics Inc | 13.45m | -178.23m | 235.73m | 181.00 | -- | 0.6506 | -- | 17.53 | -1.65 | -1.65 | 0.1237 | 3.18 | 0.0259 | -- | 4.75 | 74,292.82 | -34.32 | -31.82 | -37.13 | -36.05 | -- | -- | -1,325.43 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Benitec Biopharma Inc | 0.00 | -21.48m | 236.81m | 16.00 | -- | 2.84 | -- | -- | -5.35 | -5.35 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -43.53 | -103.21 | -48.09 | -123.13 | -- | 152.10 | -- | -26,432.69 | -- | -- | 0.00 | -- | -100.00 | -- | -14.35 | -- | -15.35 | -- |
| Personalis Inc | 87.49m | -91.44m | 238.79m | 223.00 | -- | 1.43 | -- | 2.73 | -1.68 | -1.68 | 1.64 | 2.36 | 0.3751 | 7.18 | 6.45 | 392,327.30 | -39.20 | -28.84 | -45.99 | -34.72 | 31.41 | 28.65 | -104.52 | -96.01 | 4.44 | -- | 0.0098 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| Mersana Therapeutics Inc | 34.84m | -74.62m | 242.90m | 123.00 | -- | 231.91 | -- | 6.97 | -0.6129 | -0.6129 | 0.286 | 0.0085 | 0.1611 | -- | 69.67 | 283,227.70 | -34.51 | -61.68 | -50.38 | -81.35 | -- | -- | -214.19 | -622.19 | -- | -- | 0.9604 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -4.08m | 243.14m | 20.00 | -- | 2.20 | -- | -- | -0.3861 | -0.3861 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -1.13 | -38.44 | -1.22 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| aTyr Pharma Inc | 235.00k | -63.82m | 250.15m | 56.00 | -- | 3.46 | -- | 1,064.46 | -0.9365 | -0.9365 | 0.0034 | 0.8617 | 0.0022 | -- | 0.12 | 4,196.43 | -58.90 | -45.45 | -67.15 | -52.74 | -- | -- | -27,155.32 | -784.19 | -- | -- | 0.0233 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Abeona Therapeutics Inc | 0.00 | -71.03m | 250.79m | 84.00 | -- | 5.49 | -- | -- | -2.29 | -2.29 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -76.10 | -53.22 | -88.88 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2895 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Lyell Immunopharma Inc | 63.00k | -203.99m | 255.93m | 224.00 | -- | 0.4431 | -- | 4,062.44 | -0.8013 | -0.8013 | 0.0003 | 2.07 | 0.00009 | -- | -- | 281.25 | -28.85 | -- | -30.32 | -- | -- | -- | -323,792.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Ocugen Inc | 9.33m | -49.67m | 262.45m | 65.00 | -- | 6.44 | -- | 28.14 | -0.1839 | -0.1839 | 0.0351 | 0.14 | 0.1365 | -- | -- | 143,492.30 | -72.71 | -83.56 | -90.53 | -97.79 | -- | -- | -532.51 | -2,921.94 | -- | -- | 0.0663 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 264.12m | 82.00 | -- | 1.31 | -- | -- | -- | -- | -- | 8.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.001 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Poseida Therapeutics Inc | 150.86m | -60.76m | 264.13m | 350.00 | -- | 3.03 | -- | 1.75 | -0.635 | -0.635 | 1.56 | 0.8953 | 0.5064 | -- | 12.88 | 457,145.50 | -20.39 | -40.70 | -27.58 | -47.72 | -- | -- | -40.28 | -233.49 | -- | -6.89 | 0.4032 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
Data as of Nov 22 2024. Currency figures normalised to Mersana Therapeutics Inc's reporting currency: US Dollar USD
42.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 30 Sep 2024 | 19.36m | 15.79% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.73m | 6.30% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 7.02m | 5.72% |
| Citadel Advisors LLCas of 30 Sep 2024 | 4.38m | 3.57% |
| Rock Springs Capital Management LPas of 30 Sep 2024 | 3.05m | 2.48% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.73m | 2.22% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.41m | 1.97% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2024 | 2.22m | 1.81% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2024 | 1.92m | 1.57% |
| SilverArc Capital Management LLCas of 11 Oct 2024 | 1.75m | 1.43% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
